SG11201810294QA - Treatment for parkinson's disease - Google Patents
Treatment for parkinson's diseaseInfo
- Publication number
- SG11201810294QA SG11201810294QA SG11201810294QA SG11201810294QA SG11201810294QA SG 11201810294Q A SG11201810294Q A SG 11201810294QA SG 11201810294Q A SG11201810294Q A SG 11201810294QA SG 11201810294Q A SG11201810294Q A SG 11201810294QA SG 11201810294Q A SG11201810294Q A SG 11201810294QA
- Authority
- SG
- Singapore
- Prior art keywords
- pharma
- sun
- road
- advanced research
- tandalja
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201621019087 | 2016-06-02 | ||
| IN201621019185 | 2016-06-02 | ||
| PCT/IN2017/050224 WO2017208267A1 (en) | 2016-06-02 | 2017-06-02 | Treatment for parkinson's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810294QA true SG11201810294QA (en) | 2018-12-28 |
Family
ID=59388123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810294QA SG11201810294QA (en) | 2016-06-02 | 2017-06-02 | Treatment for parkinson's disease |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US10849887B2 (es) |
| EP (2) | EP3463351B1 (es) |
| JP (1) | JP6974357B2 (es) |
| KR (1) | KR102508288B1 (es) |
| CN (1) | CN109475539B (es) |
| AU (1) | AU2017273415B2 (es) |
| BR (1) | BR112018074439A2 (es) |
| CA (1) | CA3024976A1 (es) |
| CL (1) | CL2018003431A1 (es) |
| DK (1) | DK3463351T3 (es) |
| ES (1) | ES2914782T3 (es) |
| HR (1) | HRP20220683T1 (es) |
| HU (1) | HUE059387T2 (es) |
| IL (1) | IL263188B (es) |
| LT (1) | LT3463351T (es) |
| MX (1) | MX2018014944A (es) |
| MY (1) | MY193754A (es) |
| PH (1) | PH12018502457B1 (es) |
| PL (1) | PL3463351T3 (es) |
| PT (1) | PT3463351T (es) |
| RS (1) | RS63243B1 (es) |
| SG (1) | SG11201810294QA (es) |
| SI (1) | SI3463351T1 (es) |
| UA (1) | UA123018C2 (es) |
| WO (1) | WO2017208267A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9474753B2 (en) | 2012-05-02 | 2016-10-25 | Georgetown University | Treating neural disease with tyrosine kinase inhibitors |
| SG11201810294QA (en) * | 2016-06-02 | 2018-12-28 | Sun Pharma Advanced Res Co Ltd | Treatment for parkinson's disease |
| CN110606840A (zh) | 2018-06-15 | 2019-12-24 | 日产化学株式会社 | 5-炔基吡啶化合物的制造方法 |
| EA202193211A1 (ru) | 2019-06-11 | 2022-03-30 | Сан Фарма Эдванст Рисерч Компани Лтд. | Лечение синуклеопатий |
| WO2021030783A1 (en) * | 2019-08-15 | 2021-02-18 | Duke University | Compositions and methods for the treatment cancer and cns disorders |
| IL300044A (en) | 2020-07-31 | 2023-03-01 | Sun Pharma Advanced Res Co Ltd | N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl)ethynyl]-benzohydrazide for the treatment of Alzheimer's disease |
| WO2023214314A1 (en) | 2022-05-02 | 2023-11-09 | Sun Pharma Advanced Research Company Limited | Vodobatinib for reducing progression of parkinson's disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA024194B8 (ru) * | 2011-01-21 | 2016-11-30 | Сан Фарма Адвансед Ресьорч Компани Лтд | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы |
| US9474753B2 (en) | 2012-05-02 | 2016-10-25 | Georgetown University | Treating neural disease with tyrosine kinase inhibitors |
| US10150733B2 (en) * | 2015-05-18 | 2018-12-11 | Sun Pharma Advanced Research Company Ltd. | Amidoheteroaryl aroyl hydrazide ethynes |
| SG11201810294QA (en) * | 2016-06-02 | 2018-12-28 | Sun Pharma Advanced Res Co Ltd | Treatment for parkinson's disease |
-
2017
- 2017-06-02 SG SG11201810294QA patent/SG11201810294QA/en unknown
- 2017-06-02 DK DK17743097.2T patent/DK3463351T3/da active
- 2017-06-02 WO PCT/IN2017/050224 patent/WO2017208267A1/en unknown
- 2017-06-02 US US16/304,914 patent/US10849887B2/en active Active
- 2017-06-02 MX MX2018014944A patent/MX2018014944A/es unknown
- 2017-06-02 MY MYPI2018002187A patent/MY193754A/en unknown
- 2017-06-02 KR KR1020187034626A patent/KR102508288B1/ko active IP Right Grant
- 2017-06-02 UA UAA201812407A patent/UA123018C2/uk unknown
- 2017-06-02 RS RS20220497A patent/RS63243B1/sr unknown
- 2017-06-02 SI SI201731157T patent/SI3463351T1/sl unknown
- 2017-06-02 EP EP17743097.2A patent/EP3463351B1/en active Active
- 2017-06-02 PT PT177430972T patent/PT3463351T/pt unknown
- 2017-06-02 BR BR112018074439-5A patent/BR112018074439A2/pt active IP Right Grant
- 2017-06-02 ES ES17743097T patent/ES2914782T3/es active Active
- 2017-06-02 HU HUE17743097A patent/HUE059387T2/hu unknown
- 2017-06-02 CN CN201780044265.3A patent/CN109475539B/zh active Active
- 2017-06-02 LT LTEPPCT/IN2017/050224T patent/LT3463351T/lt unknown
- 2017-06-02 EP EP22169420.1A patent/EP4085912A1/en active Pending
- 2017-06-02 JP JP2018563062A patent/JP6974357B2/ja active Active
- 2017-06-02 CA CA3024976A patent/CA3024976A1/en active Pending
- 2017-06-02 AU AU2017273415A patent/AU2017273415B2/en active Active
- 2017-06-02 PL PL17743097T patent/PL3463351T3/pl unknown
- 2017-06-02 HR HRP20220683TT patent/HRP20220683T1/hr unknown
-
2018
- 2018-11-21 IL IL263188A patent/IL263188B/en unknown
- 2018-11-22 PH PH12018502457A patent/PH12018502457B1/en unknown
- 2018-11-30 CL CL2018003431A patent/CL2018003431A1/es unknown
-
2020
- 2020-10-01 US US17/061,139 patent/US11583522B2/en active Active
-
2022
- 2022-05-18 US US17/747,472 patent/US11813252B2/en active Active
-
2023
- 2023-10-11 US US18/378,901 patent/US20240066014A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810294QA (en) | Treatment for parkinson's disease | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201908569QA (en) | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same | |
| SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201407037UA (en) | Catechol o-methyltransferase activity inhibiting compounds | |
| SG11201901633WA (en) | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201407533SA (en) | Antiviral compounds | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201804888WA (en) | Velocity model update with an inversion gradient | |
| SG11201408460UA (en) | Inhibitors of the mir-15 family of micro-rnas | |
| SG11201804885TA (en) | Monomaleimide-functionalized platinum compounds for cancer therapy | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201810318RA (en) | Compounds for promoting hair growth and/or inhibiting or delaying hair loss in humans, and compositions for such uses | |
| SG11201809537VA (en) | Urea motif containing compounds and derivatives thereof as antibacterial drugs | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| SG11201408685WA (en) | Antibacterial microelement chelates and the use thereof in animal feeds | |
| SG11201809560QA (en) | Enhancer of zeste homolog 2 inhibitors | |
| SG11201407345QA (en) | Pyrazole compounds as sglt1 inhibitors |